lipocalin 2

Gene

Related News

Cancer Immunotherapy Resistance Mechanisms Revealed Through Cellular Stress and Senescence Pathways

Apr 01, 2026

Research reveals therapy-induced senescent cancer cells and the integrated stress response pathway play dual roles in cancer immunotherapy resistance. The ATF4-LCN2 axis suppresses anti-tumor immunity by promoting immunosuppressive macrophages, while senescent cells can both enhance and inhibit immune responses. These findings highlight new targets for improving immunotherapy efficacy.

Three New Strategies Target Cancer Through Protein Regulation and Immune System Activation

Feb 25, 2026

Researchers report advances in cancer treatment through three distinct approaches: repurposing a heart medication to target lymphoma enzymes, blocking stress proteins to enhance immunotherapy, and developing antibodies that restore immune system attacks on tumors.

Stress Protein LCN2 Helps Lung and Pancreatic Tumors Evade Immune Attack

Feb 19, 2026

Researchers discovered that lipocalin 2 (LCN2), a protein released by stressed cancer cells, helps lung and pancreatic tumors evade the immune system by manipulating macrophages and blocking T cell infiltration.